SCHEDULE: StemPoint Capital Discloses 1.5% Stake in Vistagen

StemPoint Capital LP, along with its general partner and Michelle Ross, reported a 1.5% beneficial ownership stake in Vistagen Therapeutics, Inc., primarily through warrants.

Summary

• StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Vistagen Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 616,749 shares of Vistagen Therapeutics, Inc. Common Stock.
• This ownership represents 1.5% of the company's outstanding Common Stock.
• The beneficial ownership is primarily derived from 616,749 shares of Common Stock issuable upon the exercise of Warrants.
• The percentage is calculated based on 39,495,451 shares outstanding as of November 12, 2025, as reported in Vistagen's Form 10-Q, plus the shares from warrants, subject to a 9.9% beneficial ownership limitation.
• The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms continued institutional interest in Vistagen Therapeutics, Inc. through a significant warrant position, without indicating any negative developments.

Positives

• Institutional investor StemPoint Capital LP maintains a beneficial ownership stake in Vistagen Therapeutics, Inc., indicating continued interest.
• The ownership is primarily through warrants, which could provide future capital to Vistagen upon exercise.

Negatives

• The filing itself does not present explicit negative information; it is a factual ownership disclosure.

Risks

• The filing does not explicitly mention company-specific risks.

Future Outlook

The filing does not contain forward-looking statements or guidance from Vistagen Therapeutics, Inc. It is a disclosure of current beneficial ownership by an institutional investor.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from Vistagen Therapeutics, Inc. management. It includes certifications from the Reporting Persons that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership, even at 1.5%, can signal a level of confidence in a company, particularly in the biotechnology sector where long-term investment horizons are common. The continued holding by StemPoint Capital suggests a sustained interest in Vistagen Therapeutics, Inc.'s potential, aligning with broader trends of specialized funds taking positions in promising therapeutic developers.

Comparison to Industry Standards

• Institutional ownership levels vary widely across industries and company stages. For a biotechnology company like Vistagen Therapeutics, Inc., a 1.5% stake by an investment firm like StemPoint Capital is a standard form of passive investment.
• While not a controlling stake, it indicates that the company has attracted attention from professional investors. For example, similar-sized biotech firms often see a diverse mix of institutional holders, with individual stakes typically ranging from under 1% to several percent, depending on the fund's strategy and the company's market capitalization and liquidity.

Stakeholder Impact

• Shareholders: The disclosure of an institutional investor's stake can provide a degree of confidence or validation for existing and potential shareholders. The exercise of warrants could lead to dilution but also provide capital.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Vistagen Therapeutics, Inc. or the Reporting Persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The filing is a routine disclosure of beneficial ownership by an institutional investor and does not contain new operational or financial performance data for Vistagen Therapeutics, Inc. While the continued institutional interest is a minor positive, it does not provide sufficient new information to warrant a change in investment strategy. Investors should hold their positions and await further operational updates or financial results from the company.

Keywords

Vistagen Therapeutics, StemPoint Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals